Allogeneic NK Cells in Cancer Treatment, Thailand

• Immunotherapy
• Immunotherapy for prostate cancer
• Immunotherapy for lung cancer
• Natural Killer Cell Therapy (NK Cell Therapy)
• Oncothermia
• Consultation with a doctor
• Video or text consultation
• 24-hr nurse services

• 3 days in the hotel

• Transfer airport-clinic-airport

Using allogeneic NK cells offers several clinical advantages, especially when compared to using the patient's own cells (Autologous), as detailed below:

1. Higher Potency and Function
Healthier Cells: Cancer patients often have a low number and impaired function of their own NK cells due to the tumor microenvironment or prior treatments (like chemotherapy).

Healthy Donor Source: Using NK cells from a healthy donor ensures a starting population of cells with higher quality and superior cytotoxic activity (cancer-killing ability).

2. Off-the-Shelf Availability
Reduced Waiting Time: Allogeneic cells can be manufactured, expanded, and cryopreserved (stored) in advance (sourced from cord blood, peripheral blood, or iPSCs). This allows for rapid administration when the patient needs treatment immediately.

Flexibility: Patients can start treatment without the delay involved in the cell collection and weeks-long expansion process required for autologous therapy.

3. Low Risk of Severe Complications
Low GVHD Risk: Unlike T-Cells, which are the main cause of severe Graft-versus-Host Disease (GVHD) (where donor cells attack the recipient's tissues), NK cells have a significantly lower risk of inducing GVHD. This makes the therapy generally safer than allogeneic stem cell transplants that rely heavily on T-cells.

4. Superior Killing Mechanism
Alloreactivity: NK cells possess specific recognition receptors (Killer Immunoglobulin-like Receptors, KIRs) that can become highly activated when there is a genetic mismatch with the patient's cancer cells. This leads to a more effective anti-cancer response, known as the "Graft-versus-Tumor" effect.

Clinical Application
Allogeneic NK Cell Therapy has shown promising results in treating hematologic malignancies (blood cancers), particularly Acute Myeloid Leukemia (AML). Extensive research is also underway to enhance its efficacy against solid tumors (e.g., lung, breast, and pancreatic cancer) by engineering NK cells (such as CAR-NK) to specifically target tumor antigens.

• Personal medical coordinator
• Medical travel arrangements — booking of air tickets and hotel rooms at special partner prices
• Patient advocacy during medical travel